The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside
- 126 Downloads
Background and Purpose
BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy.
A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018.
Results and Conclusions
Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.
KeywordsBCG unresponsive bladder cancer Gene therapy Interferon-α Instiladrin
JD literature review and manuscript writing. SM manuscript editing/data collection. DP manuscript editing/data collection. KS manuscript editing. SYH manuscript writing/editing. NP manuscript writing/editing. CD manuscript oversight/writing/editing.
The University of Texas MD Anderson SPORE in Genitourinary Cancer P50CA091846, NIH/NCI under P30CA016672.
Compliance with ethical standards
Conflict of interest
Nigel Parker: leadership, consulting, and research funding—FKD Therapies Oy. Seppo Yla-Herttulla: consultant for FKD Therapies Oy. Colin Dinney: consultant on advisory board for FKD Therapies Oy. All remaining authors declare no conflicts of interest.
Research involving human participants and/or animals
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Informed consent was obtained from all individual participants of clinical studies included in this review article.
- 3.Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMedGoogle Scholar
- 4.Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196(4):1021–1029. https://doi.org/10.1016/j.juro.2016.06.049 CrossRefPubMedGoogle Scholar
- 5.Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA (2017) Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Nat Compr Cancer Netw JNCCN 15(10):1240–1267. https://doi.org/10.6004/jnccn.2017.0156 CrossRefGoogle Scholar
- 12.Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O’Donnell M, Schoenberg MP, Steinberg G (2015) Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer (Amster, Neth) 1(1):29–30. https://doi.org/10.3233/blc-159002 CrossRefGoogle Scholar
- 13.US Department of Health and Human Service Food and Drug administration (2018) BCG unresponsive non-muscle invasive bladder cancer—developing drugs and biologics for treatment—a guideline for industry. https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandgeneTherapy/default/htm
- 17.Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Can Res 58(4):808–814Google Scholar
- 19.Joudi FN, Smith BJ, O’Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24(4):344–348. https://doi.org/10.1016/j.urolonc.2005.11.026 CrossRefPubMedGoogle Scholar
- 22.Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E (2002) Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study–FinnBladder III long-term results. J Urol 168(3):981–985. https://doi.org/10.1097/01.ju.0000026417.33622.7d CrossRefPubMedGoogle Scholar
- 23.Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J et al (1988) Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 6(3):476–483. https://doi.org/10.1200/jco.19220.127.116.116 CrossRefPubMedGoogle Scholar
- 25.Shepherd AR, Shepherd E, Brook NR (2017) Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev 3:Cd012112. https://doi.org/10.1002/14651858.cd012112.pub2 CrossRefPubMedGoogle Scholar
- 29.Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL et al (1990) Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323(9):570–578. https://doi.org/10.1056/nejm199008303230904 CrossRefPubMedGoogle Scholar
- 37.Connor RJ, Engler H, Machemer T, Philopena JM, Horn MT, Sutjipto S, Maneval DC, Youngster S, Chan TM, Bausch J, McAuliffe JP, Hindsgaul O, Nagabhushan TL (2001) Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Ther 8(1):41–48. https://doi.org/10.1038/sj.gt.3301348 CrossRefPubMedGoogle Scholar
- 38.Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF (2002) Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 9(8):687–691. https://doi.org/10.1038/sj.cgt.7700488 CrossRefPubMedGoogle Scholar
- 39.Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, Wen SF, Shinoda J, Beltran J, Nodelman M, Machemer T, Maneval DC, Nagabhushan TL, Sugarman BJ (2001) Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther 8(10):788–795. https://doi.org/10.1038/sj.cgt.7700364 CrossRefPubMedGoogle Scholar
- 40.Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ (2004) Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther J Am Soc Gene Ther 10(3):525–532. https://doi.org/10.1016/j.ymthe.2004.05.027 CrossRefGoogle Scholar
- 41.Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP (2002) Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8(4):1258–1270PubMedGoogle Scholar
- 42.Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN (2014) Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNalpha/Syn3 treatment in a phase l study. Cancer Gene Ther 21(3):91–94. https://doi.org/10.1038/cgt.2014.1 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Zhang X, Dong L, Chapman E, Benedict WF (2008) Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Ther 15(12):817–822. https://doi.org/10.1038/cgt.2008.53 CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF (2007) Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 14(3):241–250. https://doi.org/10.1038/sj.cgt.7701011 CrossRefPubMedGoogle Scholar
- 45.Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H (2005) Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 66(1):224–229. https://doi.org/10.1016/j.urology.2005.02.015 CrossRefPubMedGoogle Scholar
- 46.Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, Benedict WF (2006) Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 13(2):125–130. https://doi.org/10.1038/sj.cgt.7700865 CrossRefPubMedGoogle Scholar
- 48.Dinney CP, Fisher MB, Navai N, O’Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF (2013) Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol 190(3):850–856. https://doi.org/10.1016/j.juro.2013.03.030 CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN (2017) Intravesical rAd-IFNalpha/Syn3 for patients with high-grade, Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a Phase II Randomized Study. J Clin Oncol 35(30):3410–3416. https://doi.org/10.1200/jco.2017.72.3064 CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD (2017) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 45:54. https://doi.org/10.1016/j.urolonc.2017.07.005 CrossRefGoogle Scholar